Субклинический синдром Кушинга, обусловленный одно- и двусторонними образованиями надпочечников. Проблемы диагностики и показаний к хирургическому лечению. Обзор литературы

Субклинический синдром Кушинга, по результатам многих исследований, является одним из самых распространенных вариантов гормональной активности случайно найденной опухоли надпочечников. Данная патология определяется как автономная гиперсекреция кортизола малой интенсивности, которая не приводит к развитию специфических признаков гиперкортицизма, однако биохимическими методами выявляются нарушения в гипоталамо-гипофизарно-надпочечниковой системе. Больным с субклиническим гиперкортицизмом в большей степени, чем общей популяции, свойственны некоторые проявления метаболического синдрома, такие как ожирение, нарушение углеводного обмена, гипертония. Все эти явления в итоге могут привести к повышению рисков сердечно-сосудистых осложнений. До сих пор в мире нет определенного мнения по поводу необходимости оперативного лечения данной патологии, хотя имеются доказательства, что после удаления образования надпочечника появляются улучшения проявлений метаболического синдрома. Для понимания всех возможных рисков, связанных с наличием субклинического гиперкортицизма, необходимо разобрать причины их возникновения, а также предоставить наиболее подходящие скрининговые тесты для выявления гиперсекреции кортизола малой интенсивности.

1. Nawar R. Adrenal incidentalomas - a continuing management dilemma. Endocr Relat Cancer. 2005;12(3):585-598. https://doi.org/10.1677/erc.1.00951

2. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses*. Endocr Rev. 1995;16(4):460-484. https://doi.org/10.1210/edrv-16-4-460

3. Reincke M. Subclinical ^siting's syndrome. Endocrinol Metab Clin North Am. 2000;29(1):43-56. https://doi.org/10.1016/s0889-8529(05)70115-8

4. Nieman LK. Approach to the patient with an adrenal inciden-taloma. J Clin Endocrinol Metab. 2010;95(9):4106-4113. https://doi.org/10.1210/jc.2010-0457

5. Terzolo M, Pia A, Reimondo G. Subclinical Сushing's syndrome: Definition and management. Clin Endocrinol. 2012;76(1):12-18. https://doi.org/10.1111/j.1365-2265.2011.04253.x.

6. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. 2011;96(7):2004-2015. https://doi.org/10.1210/jc.2011-0085

7. Reincke M, Nieke J, Krestin GP, et al. Preclinical Сushing's syndrome in adrenal "incidentalomas": Comparison with adrenal Сushing's syndrome. J Clin Endocrinol Metab. 1992;75(3):826-832. https://doi.org/10.1210/jcem.75.3.1517373

8. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab. 2000;85(2): 637-644. https://doi.org/10.1210/jcem.85.2.6372

9. Beierwaltes WH, Sturman MF, Ryo U, et al. Imaging functional nodules of the adrenal glands with 131-I-19-iodocholesterol. J Nucl Med. 1974;15:246-251.

10. Bulow B, Jansson S, Juhlin C, et al. Adrenal incidentaloma -follow-up results from a swedish prospective study. Eur J Endocrinol. 2006;154(3):419-423. https://doi.org/10.1530/eje.1.02110.

11. Barzon L, Fallo F, Sonino N, et al. Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol. 2002;146(1):61-66. https://doi.org/10.1530/eje.0.1460061

12. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. https://doi.org/10.1210/er.2002-0031.

13. Cao C, Yang X, Li L, et al. Increased expression of cyp17 and cyp11b1 in subclinical Cushing's syndrome due to adrenal adenomas. Int J Urol. 2011;18(10):691-696. https://doi.org/10.1111/j.1442-2042.2011.02836.x

14. Mitsuhiro K, Masashi D, Takashi Y, et al. Epigenetic Controls of CYP11B2 and CYP11B1 Gene in Subclinical Cushing Syndrome Associated with Overproduction of Aldosterone. Endocrine Society's 96th Annual Meeting and Expo, June 21-24, 2014. Chicago; 2014.

15. Di Dalmazi G, Kisker C, Calebiro D, et al. Novel somatic mutations in the catalytic subunit of the protein kinase as a cause of adrenal Cushing's syndrome: A european multicentric study. J Clin Endocrinol Metab. 2014;99(10):E2093-E2100. https://doi.org/10.1210/jc.2014-2152

16. Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: Results from a long-term follow-up study. Clin Endocrinol. 2009;70(5):674-679. https://doi.org/10.1111/j.1365-2265.2008.03492.x

17. Terzolo M, Osella G, Ali A, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clin Endocrinol. 1998;48(1):89-97. https://doi.org/10.1046/j.1365-2265.1998.00357.x.

18. Terzolo M, Pia A, A№ A, et al. Adrenal incidentaloma: A new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998-1003. https://doi.org/10.1210/jcem.87.3.8277

19. Osella G, Terzolo M, Borretta G, et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab. 1994;79(6):1532-1539. https://doi.org/10.1210/jcem.79.6.7989452

20. Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: An unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol. 1996; 44(6):717-722. https://doi.org/10.1046/j.1365-2265.1996.737558.x

21. Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: An italian multicenter study. J Clin Endocrinol Metab. 2009;94(9):3207-3214. https://doi.org/10.1210/jc.2009-0468

22. Bohdanowicz-Pawlak A, Szymczak J, et al. Subclinical Cushing's syndrome in adrenal incidentalomas--possible metabolic consequences. Endokrynol Pol. 2013;64(3):186-191.

23. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab. 2010;95(6):2736-2745. https://doi.org/10.1210/jc.2009-2387

24. Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing's syndrome in adrenal incidentalomas: A prospective randomized study. Ann Surg. 2009;249(3):388-391. https://doi.org/10.1097/SLA.0b013e31819a47d2

25. Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentalo-ma: Clinical, biochemical and surgical outcomes. Endocr J. 2003;50(4):399-408. https://doi.org/10.1507/endocrj.50.399

26. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: Clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440-1448. https://doi.org/10.1210/jcem.85.4.6515

27. Midorikawa S, Sanada H, Hashimoto S, et al. The improvement of insulin resistance in patients with adrenal inci-dentaloma by surgical resection. Clin Endocrinol. 2001; 54(6):797-804. https://doi.org/10.1046/j.1365-2265.2001.01274.x

28. Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemo-dynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol. 2003;148(2):213-219. https://doi.org/10.1530/eje.0.1480213

29. Karnieli E, Cohen P, Barzilai N, et al. Insulin resistance in Cushing's syndrome. Horm Metab Res. 2008;17(10): 518-521. https://doi.org/10.1055/s-2007-1013593

30. Stubbs M, York DA. Central glucocorticoid regulation of para-sympathetic drive to pancreatic -cells in the obese fa/fa rat. Int J Obes. 1991;15:547-553.

31. Tauchmanovа L, Rossi R, Biondi B, et al. Patients with sub-clinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. https://doi.org/10.1210/jc.2001-011766

32. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: A large cross-sectional study. Eur J Endocrinol. 2012;166(4):669-677. https://doi.org/10.1530/eje-11-1039

33. Liu Y, Mladinov D, Pietrusz JL, et al. Glucocorticoid response elements and 11-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardio-vasc Res. 2008;81(1):140-147. https://doi.org/10.1093/cvr/cvn231

34. Hamm LL, Hering-Smith KS. Pivotal role of the kidney in hypertension. Am J Med Sci. 2010;340(1):30-32. https://doi.org/10.1097/MAJ.0b013e3181e590f0

35. Rossi GP, Andreis PG, Colonna S, et al. Endothelin-1[1-31]: A novel autocrine-paracrine regulator of human adrenal cortex secretion and growth. J Clin Endocrinol Metab. 2002;87(1): 322-328. https://doi.org/10.1210/jcem.87.1.8134

36. Xiao D, Huang X, Bae S, et al. Cortisol-mediated potentiation of uterine artery contractility: Effect of pregnancy. Am J Physiol Heart Circ Physiol. 2002;283(1):H238-H246. https://doi.org/10.1152/ajpheart.00842.2001

37. Swiqtkowska-Stodulska R, Kaniuka-Jakubowska S, Wisni-ewski P, et al. Homocysteine and alpha-1 antitrypsin concentration in patients with subclinical hypercortisolemia. Adv Med Sci. 2012;57(2):302-307. https://doi.org/10.2478/v10039-012-0032-8.

38. Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: Biochemical and clinical characteristics. Eur J Endocrinol. 2012;168(2):235-241. https://doi.org/10.1530/eje-12-0777

39. Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: A multicenter longitudinal study. J Bone Miner Res. 2011;26(8):1816-1821. https://doi.org/10.1002/jbmr.398

40. Chiodini I, Torlontano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: A longitudinal study. J Clin Endocrinol Metab. 2001;86(11):5337-5341. https://doi.org/10.1210/jcem.86.11.8022

41. Zografos G, Perysinakis I, Vassilatou E. Subclinical Cushing's syndrome: Current concepts and trends. Hormones. 2014;13(3):323-337. https://doi.org/10.14310/horm.2002.1506.

42. Birsen O, Akyuz M, Dural C, et al. A new risk stratification algorithm for the management of patients with adrenal incidentalomas. Surgery. 2014;156(4):959-966. https://doi.org/10.1016/j.surg.2014.06.042.

43. Low G, Dhliwayo H, Lomas DJ. Adrenal neoplasms. Clin Radiol. 2012;67(10):988-1000. https://doi.org/10.1016/j.crad.2012.02.005.

44. Lumachi F, Marchesi P, D, et al. CT and MR imaging of the adrenal glands in cortisol-secreting tumors. Anticancer Res. 2011;31:2923-2926.

45. Vassiliadi DA, Ntali G, Vicha E, et al. High prevalence of sub-clinical hypercortisolism in patients with bilateral adrenal incidentalomas: A challenge to management. Clin Endocrinol. 2011;74(4):438-444. https://doi.org/10.1111/j.1365-2265.2010.03963.x.

46. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: Endocrine and scintigraphic correlates. J Clin Endocrinol Metab. 1998;83(1):55-62. https://doi.org/10.1210/jcem.83.1.4501

47. Tsagarakis S, Kokkoris P, Roboti C, et al. The low-dose dexa-methasone suppression test in patients with adrenal inciden-talomas: Comparisons with clinically euadrenal subjects and patients with Cushing's syndrome. Clin Endocrinol. 1998; 48(5):627-633. https://doi.org/10.1046/j.1365-2265.1998.00464.x

48. Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. https://doi.org/10.1210/jc.2008-0125

49. Stewart PM. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab. 2010;95(6):2618-2620. https://doi.org/10.1210/jc.2010-0633

50. Katabami T, Obi R, Shirai N, et al. Discrepancies in results of low- and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome. Endocr J. 2005;52(4):463-469. https://doi.org/10.1507/endocrj.52.463

51. Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzed-nicka J, et al. Incidentally discovered adrenal mass (inciden-taloma): Investigation and management of 208 patients. Clin Endocrinol. 1997;46(1):29-37. https://doi.org/10.1046/j.1365-2265.1997.d01-1751.x

52. Reimondo G, Allasino B, Bovio S, et al. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest. 2014;34(1):e1-e5. https://doi.org/10.1007/bf03346701

53. Grumbach MM. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5): 424. https://doi.org/10.7326/0003-4819-138-5-200303040-00013

54. Zeiger M, Thompson G, Duh Q-Y, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. EndocrPract. 2009;15(5):450-453. https://doi.org/10.4158/ep.15.5.450.

55. Ambrosi B, Peverelli S, Passini E, et al. Abnormalities of endocrine function in patients with clinically "silent" adrenal masses. Eur J Endocrinol. 1995;132(4):422-428. https://doi.org/10.1530/eje.0.1320422

56. Caplan RH. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg. 1994;129(3):291. https://doi.org/10.1001/archsurg.1994.01420270067016

57. Reincke M, Fassnacht M, Vath S, et al. Adrenal incidentalo-mas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22:757-761.

58. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-439. https://doi.org/10.1016/j.ecl.2005.01.008

59. Flecchla D, Mazza E, Carllni M, et al. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: A marker of adrenocortical tumour. Clin Endocrinol. 1995; 42(2):129-134. https://doi.org/10.1111/j.1365-2265.1995.tb01852.x

60. Masserini B, Morelli V, Bergamaschi S, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal inciden-taloma. Eur J Endocrinol. 2008;160(1):87-92. https://doi.org/10.1530/eje-08-0485

61. Raff H. A physiologic approach to diagnosis of the Cushing's syndrome. Ann Intern Med. 2003;138(12):980. https://doi.org/10.7326/0003-4819-138-12-200306170-00010

62. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: A consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602. https://doi.org/10.1210/jc.2003-030871

63. Kaltsas G, Chrisoulidou A, Piaditis G, et al. Current status and controversies in adrenal incidentalomas. Trends Endocrinol Metab. 2012;23(12):602-609. https://doi.org/10.1016/j.tem.2012.09.001

64. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous sub-clinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2014;29(5):471-482. https://doi.org/10.1007/bf03344133

65. Elfenbein DM, Scarborough JE, Speicher PJ, et al. Comparison of laparoscopic versus open adrenalectomy: Results from american college of surgeons-national surgery quality improvement project. J Surg Res. 2013;184(1):216-220. https://doi.org/10.1016/j.jss.2013.04.014

66. Tsuiki M, Tanabe A, Takagi S, et al. Cardiovascular risks and their long-term clinical outcome in patients with subclini-cal Cushing's syndrome. Endocr J. 2008;55(4):737-745. https://doi.org/10.1507/endocrj.K07E-177

67. Akaza I, Yoshimoto T, Iwashima F, et al. Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment. Hypertens Res. 2011;34(10):1111-1115. https://doi.org/10.1038/hr.2011.90

68. Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery. 2012; 152(6):991-997. https://doi.org/10.1016/j.surg.2012.08.054

69. Terzolo M, Stigliano A, Chiodini I, et al. Ame position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. https://doi.org/10.1530/eje-10-1147

70. Perysinakis I, Marakaki C, Avlonitis S, et al. Laparoscopic adrenalectomy in patients with subclinical Cushing's syndrome. Surg Endosc. 2013;27(6):2145-2148. https://doi.org/10.1007/s00464-012-2730-5

71. Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: An italian multicenter study. J Clin Endocrinol Metab. 2014:jc.2013-3527. https://doi.org/10.1210/jc.2013-3527

72. Cawood TJ, Hunt PJ, O'shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513-527. https://doi.org/10.1530/eje-09-0234

73. Young WF. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. https://doi.org/10.1056/NEJMcp065470

74. Bourdeau I. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperpla-sia with subclinical Cushing's syndrome. J Clin Endocrinol Metab. 2001;86(11):5534-5540. https://doi.org/10.1210/jc.86.11.5534

75. Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with sub-clinical autonomous cortisol hypersecretion: A prospective clinical study. Clin Endocrinol. 2004;61(3):311-319. https://doi.org/10.1111/j.1365-2265.2004.02048.x

76. Lacroix A, Baldacchino V, Bourdeau I, et al. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab. 2004;15(8):375-382. https://doi.org/10.1016/s1043-2760(04)00188-2

77. De Groot JWB, Links TP, Themmen APN, et al. Aberrant expression of multiple hormone receptors in acth-independent macronodular adrenal hyperplasia causing Cushing's syndrome. Eur J Endocrinol. 2010;163(2):293-299. https://doi.org/10.1530/eje-10-0058

78. Groussin L, Perlemoine K, Contesse V, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral mac-ronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab. 2002;87(5):1980-1985. https://doi.org/10.1210/jcem.87.5.8458

79. Joubert M, Louiset E, Rego J-LD, et al. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: Is this explained by an overexpression of vasopressin receptors? Clin Endocrinol. 2008;68(5):692-699. https://doi.org/10.1111/j.1365-2265.2007.03106.x

80. Lacroix A. Ectopic and abnormal hormone receptors in adrenal a^hing's syndrome. Endocr Rev. 2001;22(1):75-110. https://doi.org/10.1210/er.22.1.75

81. Trejter M, Carraro G, Rucinski M, et al. Arginin-vasopressin regulates proliferative activity of the regenerating rat adrenal cortex. Int JMolMed. 2005. https://doi.org/10.3892/ijmm.15.6.993

82. Kero J, Poutanen M, Zhang F-P, et al. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. J Clin Invest. 2000; 105(5):633-641. https://doi.org/10.1172/jci7716

83. Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic р-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med. 1997;337(20):1429-1434. https://doi.org/10.1056/nejm199711133372004

84. Katz MS, Kelly TM, Dax EM, et al. Ectopic в-adrenergic receptors coupled to adenylate cyclase in human adreno-cortical carcinomas*. J Clin Endocrinol Metab. 1985;60(5): 900-909. https://doi.org/10.1210/jcem-60-5-900

85. Goyal A, Panchani R, Varma T, et al. Adrenal incidentaloma: A case of pheochromocytoma with sub-clinical Cushing's syndrome. Indian J Endocrinol Metab. 2013;17(7):246. https://doi.org/10.4103/2230-8210.119587

86. Kimura T, Usui T, Inamoto S, et al. Pheochromocytoma with subclinical Cushing's syndrome caused by corticomedullary mixed tumor of the adrenal gland. J Clin Endocrinol Metab. 2009;94(3):746-747. https://doi.org/10.1210/jc.2008-2013

87. Mazzuco TL, Thomas M, Martinie M, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras EndocrinolMetabol. 2007;51(9):1452-1462. https://doi.org/10.1590/s0004-27302007000900007

88. Lacroix A, Hamet P, Boutin J-M. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome. N Engl J Med. 1999;341(21):1577-1581. https://doi.org/10.1056/nejm199911183412104.